Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Shares Outstanding (Weighted Average) (2017 - 2020)

Historic Shares Outstanding (Weighted Average) for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to $11.1 million.

  • Monopar Therapeutics' Shares Outstanding (Weighted Average) rose 1964.16% to $11.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was $11.1 million, marking a year-over-year increase of 1964.16%. This contributed to the annual value of -$0.83 for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2020, Monopar Therapeutics' Shares Outstanding (Weighted Average) is $11.1 million, which was up 1964.16% from $10.6 million recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $11.1 million in Q3 2020 and a low of $8.3 million during Q1 2017
  • For the 4-year period, Monopar Therapeutics' Shares Outstanding (Weighted Average) averaged around $9.4 million, with its median value being $9.3 million (2018).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first changed by 0.0% in 2019, then skyrocketed by 1964.16% in 2020.
  • Quarter analysis of 4 years shows Monopar Therapeutics' Shares Outstanding (Weighted Average) stood at $8.8 million in 2017, then grew by 5.8% to $9.3 million in 2018, then increased by 0.32% to $9.3 million in 2019, then grew by 19.26% to $11.1 million in 2020.
  • Its Shares Outstanding (Weighted Average) stands at $11.1 million for Q3 2020, versus $10.6 million for Q2 2020 and $10.6 million for Q1 2020.